Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins latest update

Pediatr Pulmonol. 2021 Jun;56(6):1784-1788. doi: 10.1002/ppul.25282. Epub 2021 Feb 1.

Authors

Quovadis J Epps¹, Kevin L Epps², Jeffery T Zobell^{3

4}

Affiliations

¹ College of Pharmacy and Pharmaceutical Sciences, Florida Agricultural and Mechanical University, Jacksonville, Florida, USA.
² Department of Pharmacy, The Mayo Clinic, Jacksonville, Florida, USA.
³ Department of Pharmacy, Intermountain Primary Children's Hospital, Salt Lake City, Utah, USA.
⁴ Primary Children's Cystic Fibrosis Center, Salt Lake City, Utah, USA.

PMID: 33524241
DOI: 10.1002/ppul.25282

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use
Cephalosporins / therapeutic use
Cystic Fibrosis* / complications
Cystic Fibrosis* / drug therapy
Humans
Penicillins / therapeutic use
Pseudomonas Infections* / complications
Pseudomonas Infections* / drug therapy
Pseudomonas aeruginosa

Substances

Anti-Bacterial Agents
Cephalosporins
Penicillins